FDA Brief

Warning letters Drugs

FDA warning letter to

FITISH

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

What happened

In March 2026, FDA reviewed fitish.com and found it offered compounded semaglutide and tirzepatide drug products. FDA said pictured labels named FITISH, suggesting FITISH made the drugs when it does not, and website claims compared the active ingredients to Ozempic, Mounjaro, and Zepbound, implying FDA approval. FDA said these representations made the products misbranded.

What FDA found

  1. The website labels show FITISH on compounded semaglutide and tirzepatide products, suggesting FITISH is the compounder even though the letter says it is not.

    FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)
  2. The website says semaglutide is the active ingredient in Ozempic, which FDA says implies the compounded product is FDA-approved or evaluated when it is not.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The website says tirzepatide is the active ingredient in Mounjaro and Zepbound, which FDA says implies the compounded product is FDA-approved or evaluated when it is not.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. FDA says introducing these misbranded drug products into interstate commerce is prohibited.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA tells FITISH to respond in writing within 15 business days to the Office of Compounding Quality and Compliance, identify the entities that produce the compounded drugs, provide sample labeling, and correct or remove other misleading website claims. It also must investigate root causes and take corrective and preventive measures.

Who should pay attention

  • telehealth and e-commerce companies selling compounded GLP-1 drugs
  • compounding pharmacies and contract manufacturers whose products are advertised by other brands
  • marketing and regulatory teams for wellness brands making drug-related claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low